Guangzhou-based biotechnology company Magpie Pharmaceuticals announced on Monday that it has raised a nearly RMB100 million (US$14.8 million) series B financing round from Chinese venture capital firm Sangel Capital.
Chinese Biotech Firm Magpie Pharmaceuticals Raises Nearly $15M In Series B Round comes originally from China Money Network. All Rights Reserved.